NCT05644977

A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

A Phase 1, Randomized, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Emraclidine Following Multiple Oral Doses in Healthy Elderly Participants (Part A) and to Evaluate the Safety and Tolerability of Emraclidine in Participants With Dementia Due to Alzheimer's Disease (Part B)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 55 Years – 90 Years
• Healthy volunteers: Accepted

Summary

The primary purpose of the study is to evaluate the safety and tolerability of emraclidine administered orally to healthy elderly participants in Part A (multiple ascending doses) and participants with dementia due to Alzheimer's disease (AD) in Part B.

Conditions

• Healthy Participants
• Alzheimer's Disease Dementia

Interventions

Type	Name	Description
DRUG	Emraclidine	Oral tablets
DRUG	Placebo	Oral tablets

Timeline

• Start date: 2022-12-02
• Primary completion: 2025-04-14
• Completion: 2025-04-14
• First posted: 2022-12-09
• Last updated: 2025-05-02

Locations

11 sites across 1 country: United States

Regulatory

• FDA-regulated drug study